Inhibikase Therapeutics, Inc.股价重挫17.86% 市值跌2849.28万美元

市场透视2025-01-30

北京时间2025年01月30日22时32分，Inhibikase Therapeutics, Inc.（IKT.us）股票出现异动，股价快速下挫17.86%。截至发稿，该股报2.30美元/股，成交量6.8682万股，换手率0.10%，振幅8.93%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-5.78百万美元，每股收益-0.65美元，毛利-6568.00美元，市盈率-0.74倍。机构...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2507621305?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-30 22:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2507621305","market":"us","top_or_hot":-1,"title":"Inhibikase Therapeutics, Inc.股价重挫17.86% 市值跌2849.28万美元","media":"市场透视","content":"<div>\n<p>北京时间2025年01月30日22时32分，Inhibikase Therapeutics, Inc.（IKT.us）股票出现异动，股价快速下挫17.86%。截至发稿，该股报2.30美元/股，成交量6.8682万股，换手率0.10%，振幅8.93%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-5.78百万美元，每股收益-0.65美元，毛利-6568.00美元，市盈率-0.74倍。机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223226a234554c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibikase Therapeutics, Inc.股价重挫17.86% 市值跌2849.28万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibikase Therapeutics, Inc.股价重挫17.86% 市值跌2849.28万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-30 22:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223226a234554c&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2025年01月30日22时32分，Inhibikase Therapeutics, Inc.（IKT.us）股票出现异动，股价快速下挫17.86%。截至发稿，该股报2.30美元/股，成交量6.8682万股，换手率0.10%，振幅8.93%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-5.78百万美元，每股收益-0.65美元，毛利-6568.00美元，市盈率-0.74倍。机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223226a234554c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IKT","symbol_name":"Inhibikase Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223226a234554c&s=b","article_id":"2507621305","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223226a234554c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2507621305","pubTimestamp":1738247546,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2025年01月30日22时32分，Inhibikase Therapeutics, Inc.股票出现异动，股价快速下挫17.86%。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病，帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IKT":"Inhibikase Therapeutics, Inc.","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Inhibikase Therapeutics, Inc. 's stock plunges 17.86%, its market value falls by $28.4928 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"IKT":1},"content_text":"北京时间2025年01月30日22时32分，Inhibikase Therapeutics, Inc.（IKT.us）股票出现异动，股价快速下挫17.86%。截至发稿，该股报2.30美元/股，成交量6.8682万股，换手率0.10%，振幅8.93%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-5.78百万美元，每股收益-0.65美元，毛利-6568.00美元，市盈率-0.74倍。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。Inhibikase Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Kazia Therapeutics Limited涨幅较大，Kazia Therapeutics Limited、Alterity Therapeutics Limited、Silexion Therapeutics Corp较为活跃，换手率分别为600.65%、123.48%、98.50%，振幅较大的相关个股有Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 (To Pur Com)，振幅分别为21.38%、18.28%、15.36%。Inhibikase Therapeutics, Inc.公司简介：Inhibikase Therapeutics Inc 是一家临床阶段制药公司，致力于开发蛋白激酶抑制剂疗法，以改变帕金森病（PD），帕金森病相关疾病和其他 Abelson 酪氨酸激酶疾病的病程。其多治疗产品线主要关注神经退行性疾病，其项目利用 Risvodetinib（也称为 IkT-148009），一种非受体 Abelson 酪氨酸激酶的选择性抑制剂，也针对大脑内部和外部的帕金森病的治疗以及由阿贝尔森酪氨酸激酶引起的其他疾病。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2507621305","isCrawlerRequest":true}